| | | | | | Préparation | Taille des prés. | PEF | PP | QP | CQ | Composition | Titulaire de l'aut. | Cat. | | | | |
|---|
|
| octobre 2024 - 72 Spécialités |
|
| | | IPro | | | Progesterone LEMAN 100 mg | 30 | 4.04 | 13.65 | 10% | | Capsules molles: Progesteronum 100 mg | Leman SKL SA | B / LS / SG | FB | | G |  |
| | | IPro | | | Progesterone LEMAN 100 mg | 90 | 10.32 | 27.65 | 10% | | Capsules molles: Progesteronum 100 mg | Leman SKL SA | B / LS / SG | FB | | G | |
| | | IPro | | | Progesterone LEMAN 200 mg | 15 | 4.04 | 13.65 | 10% | | Capsules molles: Progesteronum 200 mg | Leman SKL SA | B / LS / SG | FB | | G | |
| | | IPro | | | Progesterone LEMAN 200 mg | 45 | 10.32 | 27.65 | 10% | | Capsules molles: Progesteronum 200 mg | Leman SKL SA | B / LS / SG | FB | | G | |
| | | IPro | IPat | | Laurak 250 mg | 30 | 8.41 | 25.55 | 10% | | Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 250 mg | Neuraxpharm
Switzerland AG | B / LS / SG | FB | | G | |
| | | IPro | IPat | | Laurak 250 mg | 90 | 21.45 | 39.75 | 10% | | Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 250 mg | Neuraxpharm
Switzerland AG | B / LS / SG | FB | | G | |
| | | IPro | IPat | | Laurak 250 mg | 180 | 39.86 | 59.75 | 10% | | Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 250 mg | Neuraxpharm
Switzerland AG | B / LS / SG | FB | | G | |
| | | IPro | | | Laurak 500 mg | 20 | 9.80 | 27.05 | 10% | | Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 500 mg | Neuraxpharm
Switzerland AG | B / LS / SG | FB | | G | |
| | | IPro | | | Laurak 500 mg | 90 | 40.53 | 60.75 | 10% | | Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 500 mg | Neuraxpharm
Switzerland AG | B / LS / SG | FB | | G | |
| | | IPro | | | Laurak 500 mg | 180 | 79.97 | 103.95 | 10% | | Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 500 mg | Neuraxpharm
Switzerland AG | B / LS / SG | FB | | G | |
| | | IPro | | | Laurak 750 mg | 30 | 20.71 | 38.95 | 10% | | Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 750 mg | Neuraxpharm
Switzerland AG | B / LS / SG | FB | | G | |
| | | IPro | | | Laurak 750 mg | 90 | 59.48 | 81.10 | 10% | | Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 750 mg | Neuraxpharm
Switzerland AG | B / LS / SG | FB | | G | |
| | | IPro | | | Laurak 750 mg | 180 | 116.66 | 143.30 | 10% | | Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 750 mg | Neuraxpharm
Switzerland AG | B / LS / SG | FB | | G | |
| | | IPro | | | Laurak 1000 mg | 30 | 27.61 | 46.45 | 10% | | Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 1000 mg | Neuraxpharm
Switzerland AG | B / LS / SG | FB | | G | |
| | | IPro | | | Laurak 1000 mg | 90 | 79.31 | 103.20 | 10% | | Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 1000 mg | Neuraxpharm
Switzerland AG | B / LS / SG | FB | | G | |
| | | IPro | | | Laurak 1000 mg | 180 | 155.54 | 186.65 | 10% | | Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 1000 mg | Neuraxpharm
Switzerland AG | B / LS / SG | FB | | G | |
| | | IPro | | | Laurak 1500 mg | 30 | 35.20 | 54.70 | 10% | | Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 1500 mg | Neuraxpharm
Switzerland AG | B / LS / SG | FB | | G | |
| | | IPro | | | Laurak 1500 mg | 90 | 89.76 | 114.05 | 10% | | Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 1500 mg | Neuraxpharm
Switzerland AG | B / LS / SG | FB | | G | |
| | | IPro | | | Laurak 1500 mg | 180 | 166.85 | 197.90 | 10% | | Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 1500 mg | Neuraxpharm
Switzerland AG | B / LS / SG | FB | | G | |
| L | | IPro | | | Winrevair 45 mg | | 5956.94 | 6419.60 | 10% | | Lyophilisat et solvant: Sotaterceptum 45 mg | MSD Merck Sharp &
Dohme AG | B / LS | FB | | G | |
| L | | IPro | | | Winrevair 45 mg | 2 | 11913.87 | 12531.45 | 10% | | Lyophilisat et solvant: Sotaterceptum 45 mg | MSD Merck Sharp &
Dohme AG | B / LS | FB | | G | |
| L | | IPro | | | Winrevair 60 mg | | 7942.58 | 8456.90 | 10% | | Lyophilisat et solvant: Sotaterceptum 60 mg | MSD Merck Sharp &
Dohme AG | B / LS | FB | | G | |
| L | | IPro | | | Winrevair 60 mg | 2 | 15885.16 | 16605.95 | 10% | | Lyophilisat et solvant: Sotaterceptum 60 mg | MSD Merck Sharp &
Dohme AG | B / LS | FB | | G | |
| L | | IPro | | | Yuvanci 10 mg/40 mg | 30 | 2736.57 | 2992.60 | 10% | | Comprimés filmés: 2 Principes actifs | Janssen-Cilag AG | B / LS | FB | | G | |
| | | IPro | | | Vyvgart 400 mg/20ml | | DDP | DDP | N.O. | | Concentré pour perfusion: Efgartigimodum Alfa 400mg / 20ml | argenx Switzerland SA | A | FB | | G | |
| | | | | | Bupropion-Mepha XR 150 mg | 30 | DDP | DDP | N.O. | | Comprimés retards: Bupropioni Hydrochloridum 150 mg | Mepha Pharma AG | B | FB | | G | |
| | | | | | Bupropion-Mepha XR 300 mg | 30 | DDP | DDP | N.O. | | Comprimés retards: Bupropioni Hydrochloridum 300 mg | Mepha Pharma AG | B | FB | | G | |
| | | | | | Co-Losartan Spirig HC 50
mg/12.5 mg | 28 | DDP | DDP | N.O. | | Comprimés filmés: 2 Principes actifs | Spirig HealthCare AG | B | FB | | G | |
| | | | | | Co-Losartan Spirig HC 50
mg/12.5 mg | 98 | DDP | DDP | N.O. | | Comprimés filmés: 2 Principes actifs | Spirig HealthCare AG | B | FB | | G | |
| | | | | | Co-Losartan Spirig HC 100
mg/12.5 mg | 28 | DDP | DDP | N.O. | | Comprimés filmés: 2 Principes actifs | Spirig HealthCare AG | B | FB | | G | |
| | | | | | Co-Losartan Spirig HC 100
mg/12.5 mg | 98 | DDP | DDP | N.O. | | Comprimés filmés: 2 Principes actifs | Spirig HealthCare AG | B | FB | | G | |
| | | | | | Co-Losartan Spirig HC 100
mg/25 mg | 28 | DDP | DDP | N.O. | | Comprimés filmés: 2 Principes actifs | Spirig HealthCare AG | B | FB | | G | |
| | | | | | Co-Losartan Spirig HC 100
mg/25 mg | 98 | DDP | DDP | N.O. | | Comprimés filmés: 2 Principes actifs | Spirig HealthCare AG | B | FB | | G | |
| | | | | | Eletriptan Spirig HC 40 mg | 4 | DDP | DDP | N.O. | | Comprimés filmés: Eletriptanum 40 mg | Spirig HealthCare AG | B | FB | | G | |
| | | | | | Eletriptan Spirig HC 40 mg | 6 | DDP | DDP | N.O. | | Comprimés filmés: Eletriptanum 40 mg | Spirig HealthCare AG | B | FB | | G | |
| | | | | | Eletriptan Spirig HC 40 mg | 20 | DDP | DDP | N.O. | | Comprimés filmés: Eletriptanum 40 mg | Spirig HealthCare AG | B | FB | | G | |
| | | | | | Eletriptan Spirig HC 80 mg | 6 | DDP | DDP | N.O. | | Comprimés filmés: Eletriptanum 80 mg | Spirig HealthCare AG | B | FB | | G | |
| | | | | | Eletriptan Spirig HC 80 mg | 20 | DDP | DDP | N.O. | | Comprimés filmés: Eletriptanum 80 mg | Spirig HealthCare AG | B | FB | | G | |
| | | IPro | | | Filspari 200 mg | 30 | DDP | DDP | N.O. | | Comprimés filmés: Sparsentanum 200 mg | Vifor (International) AG | B | FB | | G | |
| | | IPro | | | Filspari 400 mg | 30 | DDP | DDP | N.O. | | Comprimés filmés: Sparsentanum 400 mg | Vifor (International) AG | B | FB | | G | |
| | | IPro | | | Filspari 400 mg | 90 | DDP | DDP | N.O. | | Comprimés filmés: Sparsentanum 400 mg | Vifor (International) AG | B | FB | | G | |
| | | | | | Lytgobi 4 mg | 21 | DDP | DDP | N.O. | | Comprimés filmés: Futibatinibum 4 mg | Taiho Oncology Europe
GmbH | A | FB | | G | |
| | | | | | Lytgobi 4 mg | 28 | DDP | DDP | N.O. | | Comprimés filmés: Futibatinibum 4 mg | Taiho Oncology Europe
GmbH | A | FB | | G | |
| | | | | | Lytgobi 4 mg | 35 | DDP | DDP | N.O. | | Comprimés filmés: Futibatinibum 4 mg | Taiho Oncology Europe
GmbH | A | FB | | G | |
| | | IPro | | | Pomalidomid-Teva Mepha 1 mg | 14 | DDP | DDP | N.O. | | Capsules: Pomalidomidum 1 mg | Teva Pharma AG | A | FB | | G | |
| | | IPro | | | Pomalidomid-Teva Mepha 1 mg | 21 | DDP | DDP | N.O. | | Capsules: Pomalidomidum 1 mg | Teva Pharma AG | A | FB | | G | |
| | | IPro | | | Pomalidomid-Teva Mepha 2 mg | 14 | DDP | DDP | N.O. | | Capsules: Pomalidomidum 2 mg | Teva Pharma AG | A | FB | | G | |
| | | IPro | | | Pomalidomid-Teva Mepha 2 mg | 21 | DDP | DDP | N.O. | | Capsules: Pomalidomidum 2 mg | Teva Pharma AG | A | FB | | G | |
| | | IPro | | | Pomalidomid-Teva Mepha 3 mg | 14 | DDP | DDP | N.O. | | Capsules: Pomalidomidum 3 mg | Teva Pharma AG | A | FB | | G | |
| | | IPro | | | Pomalidomid-Teva Mepha 3 mg | 21 | DDP | DDP | N.O. | | Capsules: Pomalidomidum 3 mg | Teva Pharma AG | A | FB | | G | |
| | | IPro | | | Pomalidomid-Teva Mepha 4 mg | 14 | DDP | DDP | N.O. | | Capsules: Pomalidomidum 4 mg | Teva Pharma AG | A | FB | | G | |
| | | IPro | | | Pomalidomid-Teva Mepha 4 mg | 21 | DDP | DDP | N.O. | | Capsules: Pomalidomidum 4 mg | Teva Pharma AG | A | FB | | G | |
| | | | | CM | Allerxtin Sandoz 20 mg | 10 | DDP | DDP | N.O. | | Comprimés: Bilastinum 20 mg | Sandoz
Pharmaceuticals AG | D | FB | | G | |
| | | | | CM | Allerxtin Sandoz 20 mg | 30 | DDP | DDP | N.O. | | Comprimés: Bilastinum 20 mg | Sandoz
Pharmaceuticals AG | D | FB | | G | |
| | | | | CM | Allerxtin Sandoz 20 mg | 50 | DDP | DDP | N.O. | | Comprimés: Bilastinum 20 mg | Sandoz
Pharmaceuticals AG | D | FB | | G | |
| | | IPro | IPat | | Laurak 250 mg | 2 x 90 | DDP | DDP | N.O. | | Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 250 mg | Neuraxpharm
Switzerland AG | B | FB | | G | |
| | | IPro | | | Laurak 500 mg | 30 | DDP | DDP | N.O. | | Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 500 mg | Neuraxpharm
Switzerland AG | B | FB | | G | |
| | | IPro | | | Laurak 500 mg | 2 x 90 | DDP | DDP | N.O. | | Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 500 mg | Neuraxpharm
Switzerland AG | B | FB | | G | |
| | | IPro | | | Laurak 750 mg | 2 x 90 | DDP | DDP | N.O. | | Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 750 mg | Neuraxpharm
Switzerland AG | B | FB | | G | |
| | | IPro | | | Laurak 1000 mg | 2 x 90 | DDP | DDP | N.O. | | Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 1000 mg | Neuraxpharm
Switzerland AG | B | FB | | G | |
| | | IPro | | | Laurak 1500 mg | 2 x 90 | DDP | DDP | N.O. | | Granulat zur Herstellung einer Lösung zum Einnehmen: Levetiracetamum 1500 mg | Neuraxpharm
Switzerland AG | B | FB | | G | |
| | | | | | Trabectedin Spirig HC
0,25 mg | | DDP | DDP | N.O. | | Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Trabectedinum | Spirig HealthCare AG | A | FB | | G | |
| | | | | | Trabectedin Spirig HC 1 mg | | DDP | DDP | N.O. | | Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Trabectedinum 1 mg | Spirig HealthCare AG | A | FB | | G | |
| | | IPro | IPat | | Sapropterin Spirig HC 100 mg | 30 | DDP | DDP | N.O. | | Tabletten zur Herstellung einer Lösung zum Einnehmen: Sapropterini Dihydrochloridum 100 mg | Spirig HealthCare AG | B | FB | | G | |
| | | IPro | IPat | | Sapropterin Spirig HC 100 mg | 30 | DDP | DDP | N.O. | | Tabletten zur Herstellung einer Lösung zum Einnehmen: Sapropterini Dihydrochloridum 100 mg | Spirig HealthCare AG | B | FB | | G | |
| | | IPro | IPat | | Sapropterin Spirig HC 100 mg | 120 | DDP | DDP | N.O. | | Tabletten zur Herstellung einer Lösung zum Einnehmen: Sapropterini Dihydrochloridum 100 mg | Spirig HealthCare AG | B | FB | | G | |
| | | IPro | IPat | | Sapropterin Spirig HC 100 mg | 120 | DDP | DDP | N.O. | | Tabletten zur Herstellung einer Lösung zum Einnehmen: Sapropterini Dihydrochloridum 100 mg | Spirig HealthCare AG | B | FB | | G | |
| | | | | | Allerino | 10 ml | DDP | DDP | N.O. | | | Laboratoire
homéopathique D.
Schmidt-Nagel SA | D | FB | | G | |
| | | | | | Calmolla | 10 ml | DDP | DDP | N.O. | | | Laboratoire
homéopathique D.
Schmidt-Nagel SA | D | FB | | G | |
| | | | | | Calmozen | 10 ml | DDP | DDP | N.O. | | | Laboratoire
homéopathique D.
Schmidt-Nagel SA | D | FB | | G | |
| | | | | | Digestola | 10 ml | DDP | DDP | N.O. | | | Laboratoire
homéopathique D.
Schmidt-Nagel SA | D | FB | | G | |
| | | | | | Frissela | 10 ml | DDP | DDP | N.O. | | | Laboratoire
homéopathique D.
Schmidt-Nagel SA | D | FB | | G | |
